Science & Enterprise subscription

Donate to our blog

Your support will help Science & Enterprise continue to provide science news for business people and business news for scientists.

Project Aims to Boost Ebola Drug Production

Karen McDonald (University of California, Davis)

31 December 2014. A research team at University of California in Davis aims to find new ways of boosting production capacity of the experimental Ebola drug ZMapp. The 1-year project, led by UC-Davis chemical engineering and materials science professor Karen McDonald, is funded by a $200,000 rapid-response grant . . . → Read More: Project Aims to Boost Ebola Drug Production

Pump Device Shown to Deliver Parkinson’s Drug

3-D brain wiring illustration (NIH)

30 December 2014. A clinical trial testing a pump worn by Parkinson’s disease patients shows the device can continuously deliver drugs under the skin to treat severe forms of the disorder, which today requires a surgical implant. The pump made by NeuroDerm Ltd. in Rehovot, Israel is designed to . . . → Read More: Pump Device Shown to Deliver Parkinson’s Drug

Vaccine Combo Produces Ricin, Anthrax Antibodies

Anthrax spores (U.S. Food and Drug Administration)

29 December 2014. Tests of a vaccine to prevent ricin and anthrax poisoning shows it produces long-lasting antibodies against both toxins, making a single vaccine against both bioterror agents more feasible. Results of a study by biotechnology company Soligenix Inc. in Princeton, New Jersey are reported in . . . → Read More: Vaccine Combo Produces Ricin, Anthrax Antibodies

Merry Christmas/Feliz Navidad

Science and Enterprise is taking a break tomorrow and Friday for Christmas. In the spirit of the season, here is a video from a group of talented, yet little-known musicians taking part of an initiative called Playing for Change. That organization finds unknown, talented musicians worldwide, many of whom are playing on the street or . . . → Read More: Merry Christmas/Feliz Navidad

Early Trial Underway Testing Brain Cancer Drug

(Research.gov)

24 December 2014. Kinex Pharmaceuticals, a developer of cancer therapies, began an early-stage clinical trial of an experimental treatment for tumors of support cells in the brain. The Buffalo, New York biotechnology company says the first patient received the drug code-named KX2-361 in the trial taking place at Roswell Park Cancer Institute, also . . . → Read More: Early Trial Underway Testing Brain Cancer Drug

FDA Approves New Influenza Treatment

Influenza ultrastructure illustration (Dan Higgins, CDC)

23 December 2014. The U.S. Food and Drug Administration approved yesterday a drug to treat influenza infections in adults. The treatment, Rapivab, is a small molecule drug made by BioCryst Pharmaceuticals in Durham, North Carolina.

BioCryst designs and develops therapies that block enzymes involved in infectious and inflammatory . . . → Read More: FDA Approves New Influenza Treatment

Trial Testing Biologic Treatment for Hepatitis D

Liver (National Library of Medicine)

22 December 2014. An intermediate-stage clinical trial testing a biologic treatment made by Eiger BioPharmaceuticals Inc. shows lower hepatitis D virus levels among patients taking the treatment compared to a placebo. The San Carlos, California company says the treatment, called lonafarnib, also received orphan drug status by regulatory authorities . . . → Read More: Trial Testing Biologic Treatment for Hepatitis D

3-D Tissue Assembly System Designed

Jeffrey Morgan (Brown University)

22 December 2014. Medical and engineering researchers at Brown University in Providence developed a system that puts together synthetic tissue components into larger tissue assemblies, a step in the creation of synthetic organs. A description of the system from the lab of Brown bioengineering professor Jeffrey Morgan was published on . . . → Read More: 3-D Tissue Assembly System Designed

Lilly, Biotech Partner on Fast-Acting Insulin Analog

(National Institutes of Health)

19 December 2014. The pharmaceutical company Eli Lilly and Company and biotechnology company Adocia are collaborating on commercial development of Adocia’s fast-acting synthetic insulin product. Adocia, based in Lyon, France, can gain as much as $570 million in the deal, not counting royalties on future sales.

Adocia develops enhanced formulations . . . → Read More: Lilly, Biotech Partner on Fast-Acting Insulin Analog

Juno Therapeutics Raises $265 Million in IPO

(A. Kotok)

19 December 2014. Juno Therapeutics, a biotechnology company spun-off from research labs in Seattle and New York, raised some $265 million yesterday in its initial public stock offering. The Seattle enterprise developing cancer therapies that harness the immune system issued 11 million shares of common stock priced at $24.00, and trades on . . . → Read More: Juno Therapeutics Raises $265 Million in IPO